Interactions of Fluoroquinolones with Other Drugs: Mechanisms, Variability, Clinical Significance, and Management
Overview
Authors
Affiliations
Several important interactions of fluoroquinolones with other drugs have been reported in the literature. The absorption of all fluoroquinolones is almost entirely inhibited by concomitant administration of di- and trivalent cations, such as aluminum and magnesium contained in antacids. The inhibition of absorption can be significant and can potentially lead to the failure of treatment, even when fluoroquinolone doses are separated from antacid doses by hours. Certain isozymes of the cytochrome P-450 system are selectively inhibited by some fluoroquinolones. The metabolism of theophylline and caffeine is inhibited by enoxacin and ciprofloxacin such that the dosage of theophylline may need to be reduced in order to avoid toxicity. In contrast, ofloxacin and norfloxacin cause less inhibition of the metabolism of these compounds, and reduction of the theophylline dosage is not routinely required. Evidence regarding the effect of fluoroquinolones on the disposition of other drugs known to be metabolized, such as warfarin and cyclosporine, is inconclusive. In summary, the safe and effective use of fluoroquinolone antibiotics requires careful consideration of concomitant drug therapy.
An optimal antibiotic selection framework for Sepsis patients using Artificial Intelligence.
Wendland P, Schenkel-Hager C, Wenningmann I, Kschischo M NPJ Digit Med. 2024; 7(1):343.
PMID: 39613924 PMC: 11607445. DOI: 10.1038/s41746-024-01350-y.
Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness.
Liang D, Ma J, Wei B Sci Rep. 2021; 11(1):2605.
PMID: 33510326 PMC: 7843972. DOI: 10.1038/s41598-021-82044-3.
Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones.
Gisbert J Molecules. 2020; 25(21).
PMID: 33147814 PMC: 7663000. DOI: 10.3390/molecules25215084.
Pitman S, Hoang U, Wi C, Alsheikh M, Hiner D, Percival K Antibiotics (Basel). 2019; 8(3).
PMID: 31370320 PMC: 6784105. DOI: 10.3390/antibiotics8030108.
Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications.
Michalak K, Sobolewska-Wlodarczyk A, Wlodarczyk M, Sobolewska J, Wozniak P, Sobolewski B Oxid Med Cell Longev. 2017; 2017:8023935.
PMID: 29147464 PMC: 5632915. DOI: 10.1155/2017/8023935.